Reforms to National Reimbursement system and pricing processes in Europe Updates to Managed Entry and Early Access Pathways Greater adoption of Real World Evidence (RWE) Increase Cross-Border Collaboration as a potential means of controlling cost
Moderator:
Matthias Heck, Attorney-at-law, Senior Director, International TA Policy Strategy, Alexion Astra Zeneca Rare Disease
Panellist:
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine